Pacira Biosciences, Inc. (PCRX)
36.48
0.00 (0.00%)
USD |
NASDAQ |
Nov 19, 16:00
Pacira Biosciences Cash from Investing (Quarterly) : 60.81M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 60.81M |
| June 30, 2026 | 11.76M |
| March 31, 2026 | 19.44M |
| December 31, 2025 | 19.33M |
| September 30, 2025 | 43.61M |
| June 30, 2025 | 62.16M |
| March 31, 2025 | -25.63M |
| December 31, 2024 | -0.368M |
| September 30, 2024 | -52.16M |
| June 30, 2024 | -15.22M |
| March 31, 2024 | -15.53M |
| December 31, 2023 | 8.374M |
| September 30, 2023 | -4.342M |
| June 30, 2023 | 7.326M |
| March 31, 2023 | 66.18M |
| December 31, 2022 | 11.19M |
| September 30, 2022 | -47.52M |
| June 30, 2022 | 19.16M |
| March 31, 2022 | -208.02M |
| December 31, 2021 | 66.92M |
| September 30, 2021 | -35.08M |
| June 30, 2021 | 3.033M |
| March 31, 2021 | -55.66M |
| December 31, 2020 | -82.32M |
| September 30, 2020 | -202.85M |
| Date | Value |
|---|---|
| June 30, 2020 | 36.12M |
| March 31, 2020 | -28.57M |
| December 31, 2019 | -30.80M |
| September 30, 2019 | 5.625M |
| June 30, 2019 | -181.80M |
| March 31, 2019 | 78.48M |
| December 31, 2018 | -123.16M |
| September 30, 2018 | 94.46M |
| June 30, 2018 | 59.57M |
| March 31, 2018 | -10.29M |
| December 31, 2017 | 8.699M |
| September 30, 2017 | -27.48M |
| June 30, 2017 | -61.15M |
| March 31, 2017 | -143.84M |
| December 31, 2016 | -6.917M |
| September 30, 2016 | -13.32M |
| June 30, 2016 | -19.64M |
| March 31, 2016 | -21.88M |
| December 31, 2015 | 7.255M |
| September 30, 2015 | -6.84M |
| June 30, 2015 | -19.48M |
| March 31, 2015 | -1.163M |
| December 31, 2014 | 4.017M |
| September 30, 2014 | -101.80M |
| June 30, 2014 | -30.57M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Viatris, Inc. | 292.30M |
| Organon & Co. | -44.00M |
| ANI Pharmaceuticals, Inc. | -13.50M |
| Corcept Therapeutics, Inc. | -131.99M |
| Veru, Inc. | 1.802M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 50.07M |
| Cash from Financing (Quarterly) | -69.77M |
| Free Cash Flow | 169.00M |
| Free Cash Flow Per Share (Quarterly) | 1.138 |
| Free Cash Flow to Equity (Quarterly) | 118.28M |
| Free Cash Flow to Firm (Quarterly) | 49.30M |
| Free Cash Flow Yield | 11.61% |